Description
OVERVIEWProduct overview
LL-37 is the only cathelicidin-derived antimicrobial peptide identified in humans. It is produced by neutrophils and epithelial cells and forms part of the innate immune response.
Research covers direct antimicrobial activity against bacteria and biofilms, along with immunomodulatory roles in chemotaxis, angiogenesis and wound repair.
The peptide is a widely used laboratory reference standard. It is not a medicine.
SUPPLY IN IRELANDLL-37 Ireland — supplied to research laboratories
Research groups across Ireland buy LL-37 from Kensington Laboratories as a lyophilised LL-37 peptide, released only against a batch-matched certificate of analysis. Every vial of high purity LL-37 is verified by HPLC and LC-MS before it leaves the facility, so laboratories ordering LL-37 in Ireland receive material with documented purity and identity.
Laboratory LL-37 is packed for controlled storage and sent by tracked delivery in 3–5 days to Dublin, Cork, Galway, Limerick and the rest of Ireland. Delivery costs €9.90 per order. Teams planning LL37 research can review the specifications, certificate of analysis and reference list on this page before ordering.
Institutions searching for LL-37 peptide suppliers in Ireland typically compare purity, batch documentation and delivery times. Each of those is published here: a 99% HPLC purity specification, a certificate matched to the batch code on your vial, and tracked delivery in 3–5 days.
LL-37 is supplied strictly for laboratory research use only. It is not a medicine and is not for human or veterinary consumption.
SPECIFICATIONSProduct specifications
- Purity: ≥ 99% (HPLC)
- Appearance: White lyophilised powder
- Quantity: 5 mg per vial
- CAS number: 154947-66-7
- Peptide class: 37-residue cationic host defence peptide
- Also known as: Human cathelicidin antimicrobial peptide, CAP-18 fragment
- Solubility: Soluble in bacteriostatic or sterile water
- Storage temperature: Store at 2–8°C; long-term −20°C, protected from light
- Shelf life: 24 months lyophilised; 30 days reconstituted at 2–8°C
- Manufacturing standard: ISO 9001 facility, GMP-aligned solid-phase synthesis
- Batch information: Batch number and expiry printed on every vial label
RESEARCHResearch overview
The following summary is provided for educational and scientific context only. It describes what has been observed in published laboratory and animal studies and does not represent established clinical outcomes, medical advice or a claim of efficacy in humans.
Background
LL-37 is the only cathelicidin-derived antimicrobial peptide identified in humans. It is produced by neutrophils and epithelial cells and forms part of the innate immune response.
Research covers direct antimicrobial activity against bacteria and biofilms, along with immunomodulatory roles in chemotaxis, angiogenesis and wound repair.
The peptide is a widely used laboratory reference standard. It is not a medicine.
Current research areas
Published investigation clusters around a small number of biological themes. Each remains experimental and none has been established as a therapeutic effect in humans.
- Antimicrobial and antibiofilm assays
- Membrane permeabilisation studies
- Chemotaxis and innate immune signalling
- Wound repair and re-epithelialisation models
- Host defence peptide structure–activity work
Scientific context and proposed mechanisms
The peptide is cationic and amphipathic, and its primary described antimicrobial action is disruption of anionic bacterial membranes.
Separately, it is reported to act on host cells through formyl peptide receptor-like 1, which is the route usually cited for its chemotactic and angiogenic effects.
Interpreting the evidence
Most published work in this area uses cell culture or rodent models with small group sizes and short observation windows. Independent replication varies considerably between compounds, and results are sensitive to species, route, dose and endpoint.
There is no regulatory-approved human protocol for this compound. Any laboratory protocol should be defined by the model under study, institutional ethical approval, appropriate controls and predefined endpoints.
References
CERTIFICATE OF ANALYSISIndependent batch testing
Every released batch is independently tested. Match the batch number on the vial to the certificate published online.
- Batch number
- KL-LL37-2406A
- Testing laboratory
- Colmaric Analyticals
- Date tested
- 9 June 2026
- Reported purity
- 99.26%
- Method
- RP-HPLC with UV detection at 214 nm, confirmed by LC-MS
The independent result for this batch is summarised above. Contact the laboratory team if you need the full report for this batch.
